Quantcast
  • E-mail
  • Print
  • Comment
  • Font Size
  • Digg
  • del.icio.us
  • Discuss article

Noven Announces 2006 Earnings Release Date and Upcoming Investor Conference Presentation

Posted on: Thursday, 22 February 2007, 18:01 CST

Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) today announced its 2006 earnings release date as well as a scheduled investor conference presentation.

On March 1, after the close of the U.S. market, Noven is scheduled to issue a press release announcing its financial results for the quarter and year ended December 31, 2006. At 5:00 p.m. Eastern Time the same day, a conference call among management and analysts will be broadcast live via the Internet at www.noven.com, and thereafter a rebroadcast will be accessible at the same site for at least two weeks. A taped replay of the call will be available beginning the evening of March 1 through March 3 by calling 877-660-6853 (from within the U.S.) or 201-612-7415 (from outside the U.S.) and entering account number 286 and conference ID number 228057.

Noven also announced that Robert C. Strauss, its President, CEO & Chairman, is scheduled to provide an update on Noven's business and prospects at the Raymond James 28th Annual Institutional Investors Conference in Orlando on Wednesday, March 7, 2007, at 8:05 a.m. Eastern Time. The public is invited to listen to the presentation live via webcast at www.noven.com, and a replay will be available for at least two weeks at the same site.

Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Noven's prescription patches are approved in over 30 countries and include Vivelle-Dot™ (the most prescribed estrogen patch in the U.S.) and Daytrana™ (the first and only patch approved for the treatment of ADHD). A range of new patches is under development by Noven in collaboration with industry partners. Noven is committed to expanding the universe of available transdermal therapies for the benefit of patients, partners and shareholders. See www.noven.com for additional information.


Source: Business Wire

More News in this Category


Related Articles



Rating: 2.6 / 5 (8 votes)
Rate this article:
1/52/53/54/55/5

User Comments (0)

Comment on this article

Your Name
Text from the image
Comment
max 1200 chars
* All fields are required

redOrbit Friends